Camurus

Lund, Sweden — 29 May 2023 — Camurus (Nasdaq Stockholm; CAMX) announces that Fredrik Tiberg, President and CEO, will present at the Jefferies 2023 Healthcare Conference in New York on 8 June 1.30 pm local time (EDT), giving an update on the company’s recent progress.

A webcast of the presentation can be accessed via: https://wsw.com/webcast/jeff281/camx.st/2239380

For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information was submitted for publication at 10:00 am CET on 29 May 2023.